{
  "title": "Patient-Reported Outcomes in Older Adults With Transthyretin Amyloid Cardiomyopathy - JACC",
  "url": "https://www.jacc.org/doi/10.1016/j.jacadv.2025.102204",
  "summary": [
    {
      "type": "bullet",
      "text": "**KEY FINDING**: EQ-5D-5 L and MLHFQ predict all-cause mortality and HF-related hospitalization in ATTR-CM."
    },
    {
      "type": "bullet",
      "text": "**TACTICAL WIN [ROADMAP]**: Develop ePRO platforms with adaptive questionnaires to capture PROs efficiently."
    },
    {
      "type": "bullet",
      "text": "**MARKET SIGNAL [ðŸŸ¡ NOTABLE]**: FDA prioritizing PRO data for accelerated approval of rare diseases like ATTR-CM."
    },
    {
      "type": "bullet",
      "text": "**CONCERN**: Baseline differences between trial populations may limit direct comparison of PRO outcomes."
    }
  ],
  "model": "granite4:tiny-h"
}